Surmodics (SRDX) said late Thursday it disagrees with the US Federal Trade Commission's decision to challenge the company's proposed acquisition by private-equity firm GTCR, which owns a stake in medical coatings maker Biocoat.
The antitrust regulator has sued to block the deal alleging that it's anticompetitive.
The proposed merger would result in "a highly concentrated market for outsourced hydrophilic coatings and eliminate significant head-to-head competition" between Surmodics and Biocoat, the FTC said Thursday.
Surmodics said it was disappointed by the FTC's decision to begin litigation, adding that the deal was "pro-competitive."
"Surmodics intends to vigorously defend this case in court in order to complete the merger," the company said.
Surmodics shares were down 4.8% in recent premarket activity Friday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.